Table 1.

Window of opportunity trials in HNSCC

Trial	N	Agent	Control arm	Timing	Duration	Primary end point	Significant toxicity related to drug	Delay in surgery
Baumen	55	ErLotinib Desatinib Combination	Yes	Neoadj	7–21 days	Biomarker	No	NR
Schmitz	33	Cetuximab	Yes	Neoadj	21 days	Safety	No	No
Gross	47	ErLotinib ErLotinib pLus suLindac	Yes	Neoadj	7–14 days	Biomarker	No	NR
MachieLs	30	Afatinib	Yes	Neoadj	14 days	FDG-PET response	1 patient with G3 diarrhea and ARF	3 patients
Curry	39	Metformin	No	Neoadj	9–24 days	Biomarker	No	NR
Thomas	35	ErLotinib	No	Neoadj	8–29 days	Biomarker	6 patients discontinued because of G3 pruritis and G2 rash	No
Campo	107	Lapatinib	Yes	Prior to CRT	2–6 weeks	Biomarker	No	NA
Berinstein	27	IRX-2	No	Neoadj	10 days	Biomarker Safety	1 post-op wound complication possibly reLated	No
Ferris	29	NivoLumab	No	Neoadj	29 days	Safety	No	No
UppaLuri	21	PembroLizumab	No	Neoadj	14–21 days	LRR	No	No
BeLL	17	MEDI6469	No	Neoadj	8–14 days	Safety	No	No
Shayan	14	Cetuximab pLus motoLimod	No	Neoadj	21–28 days	Biomarker	No	No

LRR locoregional recurrence

Neoadj neoadjuvant prior to surgical resection